好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Absence of Serum IgG Antibodies Against the NR1 Subunit of the NMDA Receptor in Patients with Schizophrenia
Behavioral Neurology
P06 - (-)
062
BACKGROUND: In patients with anti-NMDAR encephalitis, NR1 IgG antibodies cause internalization of receptors and decrease of synaptic NMDAR currents, thus impairing brain networks supporting cognition and emotion, and causing psychotic symptoms (Dalmau et al., 2008). The main difference with schizophrenia, also characterized by diminished NMDAR activity, is that encephalitic patients are sicker, most developing abnormal movements and a catatonic state. Because brain autoimmune disorders typically range in severity, it is reasonable to postulate that a milder form of NR1 autoimmunity may occasionally cause schizophrenia and antibodies could be found in serum.
DESIGN/METHODS: Patients with their first psychotic episode referred to a regional psychiatric center in Alava, Spain, and healthy controls were recruited after written informed consent. Sera were frozen for subsequent study. After a one-year follow up, sera of patients who then met DSM-IV-TR criteria for schizophrenia-spectrum disorders and controls were tested for IgG antibodies to NR1 using previously reported criteria (Dalmau et al., 2008): immunohistochemistry on rat brain slices and dissociated rodent hippocampal neurons, and a cell-based assay expressing NR1 subunits of the NMDAR.
RESULTS: Patients (n=80) and healthy controls (n=40) groups did not differ statistically in age (29.4卤9.9 and 30.7卤9.4 years), or sex (28 and 38 percent women). Anti-NR1 IgG antibodies were not detected in either group. Both had four cases with sera reactive to other, still unidentified, neuronal surface antigens.
CONCLUSIONS: Our findings and a study of seven patients with schizophrenia (Rhoads J et al., 2011) fail to support the hypothesis that NR1 IgG antibodies are present in the sera of patients with schizophrenia. However, our study does not rule out that some patients could have antibodies only detectable in CSF.
Authors/Disclosures
Joseph C. Masdeu, MD, PhD, FAAN (Houston Methodist Neurological Institute)
PRESENTER 		Dr. Masdeu has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lilly . The institution of Dr. Masdeu has received research support from NIH. The institution of Dr. Masdeu has received research support from Houston Methodist Foundation. The institution of Dr. Masdeu has received research support from Alector. The institution of Dr. Masdeu has received research support from Aviado-Bio. Dr. Masdeu has received publishing royalties from a publication relating to health care. Dr. Masdeu has received publishing royalties from a publication relating to health care. Dr. Masdeu has received personal compensation in the range of $100,000-$499,999 for serving as a Director, Nantz Nal Alzheimer Center with HOUSTON METHODIST NEUROLOGICAL INSTITUTE.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Jose De Leon, MD (Univ Of Kentucky) No disclosure on file
Josep O. Dalmau, MD, PhD, FAAN Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas Research Institute of America. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Research & Development . Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Euroimmun, Inc. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care.
David Miller No disclosure on file